This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals To Announce Fourth-Quarter And Full-Year 2012 Financial Results On Wednesday, March 6, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full year 2012 on Wednesday, March 6, 2013 after market close. The announcement will be followed by a conference call with the investment community, on Thursday, March 7, 2013, at 8:30 a.m. EST to provide a business update and discuss its financial and operational results.

Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until March 21, 2013. The conference call can be accessed as follows:

 
CONFERENCE CALL INFORMATION
TO PARTICIPATE LIVE:     TO LISTEN TO A REPLAY:
Date:

Time:

 

Toll-free (U.S.) Dial in # :

International Dial in # :

    March 7, 2013

8:30 a.m. EST

 

(877) 407-8031

(201) 689-8031

    Available until:

Toll-free (U.S.) Dial in # :

International Dial in # :

 

Replay passcode:

Account #:

Conference ID #

    March 21, 2013

(877) 660-6853

(201) 612-7415

 

 

268

410082

           

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek ®, NAV4694, NAV5001 and RIGScan TM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,067.33 +43.27 0.24%
S&P 500 2,115.61 +7.32 0.35%
NASDAQ 5,024.1360 +18.7450 0.37%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs